B7-H3: a robust target for immunotherapy in prostate cancer

Trends Cancer. 2024 Jul;10(7):584-587. doi: 10.1016/j.trecan.2024.05.003. Epub 2024 Jun 4.

Abstract

B7-H3, an immune checkpoint glycoprotein, facilitates immune evasion and the promotion of tumors and is highly expressed on the surface of prostate cancer (PCa) cells, which makes it a feasible and robust candidate for immunotherapies against advanced prostate cancer. Here, we summarize and discuss recent findings on the suitability of targeting B7-H3 in PCa treatment.

Keywords: B7-H3; immunotherapy; prostate cancer.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • B7 Antigens* / antagonists & inhibitors
  • B7 Antigens* / genetics
  • B7 Antigens* / immunology
  • B7 Antigens* / metabolism
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunotherapy* / methods
  • Male
  • Molecular Targeted Therapy / methods
  • Prostatic Neoplasms* / immunology
  • Prostatic Neoplasms* / pathology
  • Prostatic Neoplasms* / therapy

Substances

  • B7 Antigens
  • CD276 protein, human
  • Immune Checkpoint Inhibitors